|
|
|
|
|
|
|
|
1) abstract
2) open access - pdf
Key Message: "This article summarises the evolving role and challenges of somatic BRCA mutations and BRCA methylation in ovarian cancer"
Conclusion
The activity of PARP inhibitors is now beyond germline BRCA mutation-associated ovarian cancer and more widely applicable to HRD. The therapeutic implications of BRCA epigenetic modifications are not clear......
(HRD: homologous combination deficiency)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.